Seeking Alpha

Exidavnemab phase 2a study expanded to include MSA patients

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Nasdaq

Alterity (ATHE) Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in ...
Business Insider

Alterity Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics (NASDAQ:ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 ...